Learn how accurate models can lead to better drugs for patients, and hopefully tide some transplant patients over until organs can be printed to scale.
While complex organs are still working on scaling to create perfect matches to eliminate the organ transplant list and tissue rejection, bioprinting is still finding ways into the medical industry. Models for drug screening are just one of the ways 3D bioprinting will change our lives.
As the technology begins to develop, the interest in 3D bioprinting only continues to grow. The expected explosion in market value mentioned earlier is due to the clinical applications that will become available by 2021. In addition to oncology, the cardiovascular, orthopedic, and plastic surgery fields will greatly benefit from 3D bioprinting as its ability to print tissue grafts provide greater medical advantages compared to traditional methods. Although the applied and research markets will not reach the same valuation as the clinical industry, they are still expected to more than double in the next five years.
3D bioprinting is still in a relatively fledgling state, but its impact for research and clinical applications are paramount. It has already shown to be more accurate and representative of in vivo tissue cultures and aims to be tenable to current high-throughput screening methods. Challenges in this field only serve to be opportunities to expand. We are still far from printing a beating heart, but it is not outside the realm of possibility.